Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus letrozole as neoadjuvant therapy for ER-positive HER2-negative primary breast cancer
ISRCTN31243262Phase 2Completed
- Sponsor
- Institute of Cancer Research
- Start
- Feb 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Letrozole first then combination with Palbociclib first then combination (2 arms). Primary endpoints: Change in Ki67 at 14 weeks and Clinical response by ultrasound. Started Feb 2015; status: completed.
02
Drugs
palbociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN31243262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN31243262.